Patients that have Undergone Hemodialysis Exhibit Lower Amyloid Deposition in the Brain: Evidence Supporting a Therapeutic Strategy for Alzheimer’s Disease by Removal of Blood Amyloid
The DOI matches its Crossref record; 14 of the 15 references it cites were found in a registry or an index.
Abstract
As a proof of concept that removal of blood amyloid-β (Aβ) can reduce Aβ deposition in the brains of patients with Alzheimer’s disease, cortices of patients who had undergone hemodialysis (HD), which removes Aβ from the blood, were histochemically analyzed; postmortem brain sections were stained with anti-Aβ antibodies. Brains from patients who had undergone HD had significantly fewer senile plaques than those of patient who had not undergone HD. This significant difference was also confirmed by silver staining. Our findings suggest that removal of blood Aβ by hemodialysis results in lower accumulation of Aβ in the brain.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Patients with CKD and animals undergoing unilateral nephrectomy exhibit elevated levels of circulating and cerebral Aβ, along with impaired cognition.254–256”
From Antiageing strategy for neurodegenerative diseases: from mechanisms to clinical advances (2025) · cites this paper as [256]
Citations
Cites
Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders
Zlokovic, B. V. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3114 · Cited by 2,969
Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease
Mawuenyega, K. G., Sigurdson, W., Ovod, V., Munsell, L., Kasten, T., Morris, J. C., Yarasheski, K. E., & Bateman, R. J. (2010) · Science · doi:10.1126/science.1197623 · Cited by 2,078
Intraneuronal Aβ42 Accumulation in Human Brain
Gouras, G. K., Tsai, J., Naslund, J., Vincent, B., Edgar, M., Checler, F., Greenfield, J. P., Haroutunian, V., Buxbaum, J. D., Xu, H., et al. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64700-1 · Cited by 991
Bouras, C., Hof, P. R., Giannakopoulos, P., Michel, J.-P., & Morrison, J. H. (1994) · Cerebral Cortex · doi:10.1093/cercor/4.2.138 · Cited by 280
Intraneuronal Aβ-Amyloid Precedes Development of Amyloid Plaques in Down Syndrome
Gyure, K. A., Durham, R., Stewart, W. F., Smialek, J. E., & Troncoso, J. C. (2001) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2001-125-0489-iaapdo · Cited by 248
Diffuse type of senile plaques in the brains of Alzheimer-type dementia
Yamaguchi, H., Hirai, S., Morimatsu, M., Shoji, M., & Harigaya, Y. (1988) · Acta Neuropathologica · doi:10.1007/bf00687420 · Cited by 235
Braak, H., Braak, E., Ohm, T., & Bohl, J. (1988) · Stain Technology · doi:10.3109/10520298809107184 · Cited by 171
Wiesehan, K., Buder, K., Linke, R. P., Patt, S., Stoldt, M., Unger, E., Schmitt, B., Bucci, E., & Willbold, D. (2003) · ChemBioChem · doi:10.1002/cbic.200300631 · Cited by 171
Plasma amyloid levels and the risk of AD in normal subjects in the Cardiovascular Health Study
Lopez, O. L., Kuller, L. H., Mehta, P. D., Becker, J. T., Gach, H. M., Sweet, R. A., Chang, Y. F., Tracy, R., & DeKosky, S. T. (2008) · Neurology · doi:10.1212/01.wnl.0000306696.82017.66 · Cited by 161
Amyloid β 38, 40, and 42 species in cerebrospinal fluid: More of the same?
Schoonenboom, N. S., Mulder, C., Van Kamp, G. J., Mehta, S. P., Scheltens, P., Blankenstein, M. A., & Mehta, P. D. (2005) · Annals of Neurology · doi:10.1002/ana.20508 · Cited by 120
Research works printed but not linked: 1
- KimKS, MillerDL, SapienzaVJ, ChenCMJ, BaiC, Grundke-IqbalI, CurrieJR, WisniewskiHM (1988) Production and characterization of monoclonal antibodies reactive to synthetic cerebrovascular amyloid peptide. Neurosci Res Commun 2, 121–130.
Cited by
A systemic view of Alzheimer disease — insights from amyloid-β metabolism beyond the brain
Wang, J., Gu, B. J., Masters, C. L., & Wang, Y.-J. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.111 · Cited by 808
Cheng, Y., Tian, D.-Y., & Wang, Y.-J. (2020) · Translational Neurodegeneration · doi:10.1186/s40035-020-00195-1 · Cited by 190
“Aβ deposition is observed in the brains of CKD patients [94].”
InfluentialAntiageing strategy for neurodegenerative diseases: from mechanisms to clinical advances
Jiang, Q., Liu, J., Huang, S., Wang, X.-Y., Chen, X., Liu, G.-H., Ye, K., Song, W., Masters, C. L., Wang, J., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02145-7 · Cited by 165
“256 In addition, renal insuf fi ciency also leads to increased levels of circulating uraemic neurotoxins such as parathyroid hormone and neuropeptide Y, which adversely affect hippocampal neuronal apoptosis and the permeability of the BBB, respectively.”
Jin, W., Shen, L., Bu, X., Zhang, W., Chen, S., Huang, Z., Xiong, J., Gao, C., Dong, Z., He, Y., et al. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1721-y · Cited by 129
“Previous clinical studies have suggested that dialysis reduces blood Aβ levels [22, 25, 34, 39].”
An Integrated View on Vascular Dysfunction in Alzheimer’s Disease
Klohs, J. (2019) · Neurodegenerative Diseases · doi:10.1159/000505625 · Cited by 111
Physiological β-amyloid clearance by the liver and its therapeutic potential for Alzheimer’s disease
Cheng, Y., He, C.-Y., Tian, D.-Y., Chen, S.-H., Ren, J.-R., Sun, H.-L., Xu, M.-Y., Tan, C.-R., Fan, D.-Y., Jian, J.-M., et al. (2023) · Acta Neuropathologica · doi:10.1007/s00401-023-02559-z · Cited by 110
Tian, D.-Y., Cheng, Y., Zhuang, Z.-Q., He, C.-Y., Pan, Q.-G., Tang, M.-Z., Hu, X.-L., Shen, Y.-Y., Wang, Y.-R., Chen, S.-H., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01073-6 · Cited by 100
“Indeed, peritoneal dialysis can effectively reduce brain Aβ deposition and attenuate AD-type pathologies and cognitive deficits in AD mice [31], and haemodialysis is able to reduce Aβ plaques in the brains of CKD patients [24].”
BackgroundUllah, R., Park, T. J., Huang, X., & Kim, M. O. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101451 · Cited by 78
“Likewise, similar findings were also observed in patients who had undergone HD, as evidenced by reduced brain Aβ peptide deposition in the brains of AD patients (Sakai et al., 2016).”
BackgroundResultRevisiting the role of brain and peripheral Aβ in the pathogenesis of Alzheimer's disease
Uddin, M. S., Kabir, M. T., Tewari, D., Mamun, A. A., Mathew, B., Aleya, L., Barreto, G. E., Bin-Jumah, M. N., Abdel‐Daim, M. M., & Ashraf, G. M. (2020) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2020.116974 · Cited by 76
Decourt, B., D’Souza, G. X., Shi, J., Ritter, A., Suazo, J., & Sabbagh, M. N. (2022) · Aging and disease · doi:10.14336/ad.2021.0529 · Cited by 69
“disabled patients), considering the possibility to use anti-Aβ therapies such as passive immunotherapies or dialysis [197]; (iv) supplementing patients’ diet by adding a blend of vitamins and minerals (e.”
BackgroundDisentangling the Relationship Between Chronic Kidney Disease and Cognitive Disorders
Kelly, D., & Rothwell, P. M. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.830064 · Cited by 75
Ribeiro, V. T., de Souza, L. C., & Silva, A. C. S. E. (2019) · Protein and Peptide Letters · doi:10.2174/0929866527666191230103739 · Cited by 56
Ullah, R., & Lee, E. J. (2023) · Experimental Neurobiology · doi:10.5607/en23014 · Cited by 57
“Kidney transplantation can reduce amyloid-β deposition in the plasma [298], and hemodialysis may ameliorate amyloid-β deposition in the brains of CKD patients [300, 301].”
BackgroundDamotte, V., van der Lee, S. J., Chouraki, V., Grenier‐Boley, B., Simino, J., Adams, H., Tosto, G., White, C., Terzikhan, N., Cruchaga, C., et al. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.12333 · Cited by 41
Petralla, S., Panayotova, M., Franchina, E., Fricker, G., & Puris, E. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16070948 · Cited by 49
Targeting Beta-Amyloid at the CSF: A New Therapeutic Strategy in Alzheimer’s Disease
Menéndez‐González, M., Padilla-Zambrano, H., Alvarez, G., Capetillo‐Zarate, E., Tomás‐Zapico, C., & Costa, A. D. D. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00100 · Cited by 39
“In different reports, the level of clearance achieved by this method varies significantly and ranges from what appears to be elimination throughout the CNS (Sakai et al., 2016) to the limited elimination of diffuse”
BackgroundMethodInfluentialAlbumin Exchange in Alzheimer's Disease: Might CSF Be an Alternative Route to Plasma?
Menéndez‐González, M., & Gasparovic, C. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.01036 · Cited by 29
Associations of Blood and Cerebrospinal Fluid Aβ and tau Levels with Renal Function
Sun, H., Yao, X., Li, L., Jin, W., Bai, Y., Zeng, G., Shi, A., Liang, J., Zhu, L., Liu, Y.-H., et al. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03420-w · Cited by 29
The Association of Kidney Function with Plasma Amyloid-β Levels and Brain Amyloid Deposition
Sedaghat, S., Ji, Y., Hughes, T. M., Coresh, J., Grams, M. E., Folsom, A. R., Sullivan, K., Murray, A. M., Gottesman, R. F., Mosley, T. H., et al. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-220765 · Cited by 30
Critical thinking on amyloid-beta-targeted therapy: challenges and perspectives
Sun, B., Chen, Y., Fan, D., Zhu, C., Zeng, F., & Wang, Y. (2020) · Science China Life Sciences · doi:10.1007/s11427-020-1810-y · Cited by 29
Kitaguchi, N., Tatebe, H., Sakai, K., Kawaguchi, K., Matsunaga, S., Kitajima, T., Tomizawa, H., Katô, M., Sugiyama, S., Suzuki, N., et al. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190087 · Cited by 24
Self-citationLiu, N., Haziyihan, A., Zhao, W. G., Chen, Y., & Chao, H. (2024) · Translational Neurodegeneration · doi:10.1186/s40035-024-00434-9 · Cited by 28
Wang, J., Chen, M., Masters, C. L., & Wang, Y. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13116 · Cited by 20
Nakai, S., Wakai, K., Kanda, E., Kawaguchi, K., Sakai, K., & Kitaguchi, N. (2018) · Renal Replacement Therapy · doi:10.1186/s41100-018-0154-y · Cited by 20
“Additionally, Aβ deposition was significantly weaker in the postmortem brains of patients who had undergone hemodialysis than in age-matched controls who had not undergone hemodialysis [12], and this finding is comparable to the finding in the study by Reusche et al.”
ResultSelf-citationWu, B., Liu, Y., Li, H., Zhu, L., Zeng, L., Zhang, Z., & Peng, W. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.391305 · Cited by 24
“Furthermore, hemodialysis reduces Aβ deposition in the brains of patients with AD (Sakai et al., 2016; Kitaguchi et al., 2019; Boada et al., 2020; Urayama et al., 2022).”
BackgroundKitaguchi, N., Kato, T., Matsunaga, S., Hirano, K., Iwata, K., Kawaguchi, K., Fujita, K., Takechi, H., Hasegawa, M., Yuzawa, Y., et al. (2018) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s186118 · Cited by 15
“Because E-BARS removes blood Aβs, it may remove Aβs deposited in cerebral blood vessels(24) as well as in brain parenchyma.(10) Therefore, ARIA could occur in hemodialysis patients.”
InfluentialSelf-citationCoto-Vilcapoma, A., Castilla‐Silgado, J., Fernández‐Garcia, B., Pinto-Hernández, P., Cipriani, R., Capetillo‐Zarate, E., Menéndez‐González, M., Vega, M. A. Á., & Tomás‐Zapico, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23169256 · Cited by 15
Chen, X., Wang, M., Niu, J., Ma, J., Qian, J., Ni, L., Cheng, P., You, H., & Chen, J. (2023) · Clinical Kidney Journal · doi:10.1093/ckj/sfad173 · Cited by 13
“Second, previous studies showed that the accumulation of brain A β was lower in HD patients, possibly causing an increased rate of negative results for A β positron-emission tomography ( PET ) [ 24 , 42 ], thus A β PET imaging was not collected in the present study.”
ResultRemoval of Aβ Oligomers from the Blood: A Potential Therapeutic System for Alzheimer’s Disease
Saito, Y., Sakata, M., Kobayakawa, M., Kawachi, H., Kawaguchi, K., Hiki, Y., Katô, M., Mori, M., Hasegawa, M., Ohashi, N., et al. (2020) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s241074 · Cited by 12
Self-citationKitaguchi, N., Kawaguchi, K., Yamazaki, K., Kawachi, H., Sakata, M., Kaneko, M., Katô, M., Sakai, K., Ohashi, N., Hasegawa, M., et al. (2017) · Journal of Artificial Organs · doi:10.1007/s10047-017-1012-3 · Cited by 10
Self-citationDegradation of amyloid β-peptides catalyzed by nattokinase in vivo and in vitro
Ni, A., Li, H., Wang, R., Sun, R., & Zhang, Y. (2023) · Food Science and Human Wellness · doi:10.1016/j.fshw.2023.02.042 · Cited by 9
Xie, G., Jiang, G., Huang, L., Sun, S., Wan, Y., Li, F., Wu, B., Zhang, Y., Li, X., Xiong, B., et al. (2025) · Pharmaceuticals · doi:10.3390/ph18060790 · Cited by 13
The impact of hemodiafiltration on cognitive function in patients with end-stage renal disease
Wang, X., Chen, X., Tang, Y., Zhang, L., Wang, Y., Hou, Z., Jang, W., & Yuan, Y. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.980658 · Cited by 10
“At the same time, HD removes soluble Aβ from the blood while reducing senile plaques (Sakai et al., 2016).”
BackgroundA Novel Perspective on PCSK9 in Alzheimer’s Disease: A Focus on Amyloid Beta
Zhang, H., Xu, Q. F., Zhao, Y., He, N., Ren, Z., Xiang, Q., Tang, Z., & Liu, L. (2024) · Current Medicinal Chemistry · doi:10.2174/0109298673269288231123095215 · Cited by 8
Szegeczki, V., Perényi, H., Horváth, G., Hinnah, B., Tamás, A., Radak, Z. O., Ábrahám, D., Zákány, R., Reglődi, D., & Juhász, T. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201206 · Cited by 6
Kitaguchi, N., Kawaguchi, K., Sakata, M., Aoki, H., Yamazaki, K., Kaneko, M., Kinomura, J., Katô, M., Hasegawa, M., Suzuki, N., et al. (2021) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s317104 · Cited by 4
Self-citationThe Role of Circulating Aβ Seeds in the Progression of Cerebral Amyloidosis
Gamez, N., & Morales, R. (2022) · Neuroscience Insights · doi:10.1177/26331055221123072 · Cited by 4
Altering Brain Amyloidosis by Intra-Lingual and Extra-Nasal Exposure of Aβ Aggregates
Gamez, N., Bravo-Alegria, J. B., Huang, Y., Perez-Urrutia, N., Dongarwar, D., Soto, C. A., & Morales, R. (2022) · Cells · doi:10.3390/cells11213442 · Cited by 3
Kitaguchi, N., Kawaguchi, K., & Sakai, K. (2018) · Springer eBooks · doi:10.1007/978-981-10-8488-1_10 · Cited by 3
Self-citationHasegawa, M., Kitaguchi, N., Takechi, H., Kawaguchi, K., Ito, K., Kato, T., Katô, M., Nii, N., Yamada, S., Ohashi, A., et al. (2022) · Therapeutic Apheresis and Dialysis · doi:10.1111/1744-9987.13827 · Cited by 3
“We reported that Aβ accumulation in the brains of patients undergoing hemodialysis was significantly lower than that in age-matched controls not undergoing hemodialysis in an immunohistochemical study [13].”
ResultSelf-citationPhenotyping cognitive impairment in dialysis patients: insights from experimental mouse models
Kelly, D. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1778-7
Removal of blood amyloid-β as an effective and safe therapeutic strategy for Alzheimer's disease
Kitaguchi, N., Kawaguchi, K., & Sakai, K. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-815854-8.00041-0
Self-citationSystemic Amyloid-β Metabolism in Alzheimer’s Disease
Dong-yu, F., Wang, J., Gu, B. J., Masters, C. L., & Wang, Y. (2026) · Springer eBooks · doi:10.1007/978-981-95-5222-1_7
Metadata
- Authors
- Sakai, K., Senda, T., Hata, R., Kuroda, M., Hasegawa, M., Kato, M., Abe, M., Kawaguchi, K., Nakai, S., Hiki, Y., Yuzawa, Y., & Kitaguchi, N.
- Affiliations
- Fujita Health University (JP)
- Department of Nephrology, School of Medicine, Fujita Health University, Toyoake, Japan
- Corresponding author
- Kitaguchi, Nobuya
- ORCID
- Venue
- Journal of Alzheimer’s Disease
- Publisher
- SAGE Publications
- Published
- 2016-02-20
- Volume
- 51
- Issue
- 4
- Pages
- 997-1002
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W2275719381
- Cited by
- 43
- References
- 15
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 3 · 2023: 9 · 2022: 6 · 2021: 5 · 2020: 5 · 2019: 4 · 2018: 4 · 2017: 4
- FWCI
- 3.22
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Journal of Alzheimer s Disease (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Japan Society for the Promotion of Science (25462645, 26282126, 26462772)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Clinical Neurology › Cerebrospinal fluid and hydrocephalus
- Keywords
- hemodialysis, amyloid-beta
- MeSH terms
- Aged, Aged, 80 and over, Autopsy, Brain, Renal Dialysis, Humans, Kidney Diseases, Case-Control Studies, Amyloid beta-Peptides, Silver Staining, Statistics, Nonparametric, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.